The radical anti-PCSK9 compound LIB003 considerably reduces low-density lipoprotein (LDL) ldl cholesterol ranges over 52 weeks in patients already taking maximally tolerated statins, results of…
The radical anti-PCSK9 compound LIB003 considerably reduces low-density lipoprotein (LDL) ldl cholesterol ranges over 52 weeks in patients already taking maximally tolerated statins, results of…